Search results
Showing 16 to 30 of 160 results for fibrosis
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)
This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.
View recommendations for NG117Show all sections
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261]
In development [GID-TA11297] Expected publication date: 08 May 2024
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)
Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del mutation.
In development [GID-TA11187] Expected publication date: TBC
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
outcomes in idiopathic pulmonary fibrosis:- Does ambulatory oxygen improve outcomes in idiopathic pulmonary fibrosis? Any...
treatment for idiopathic pulmonary fibrosis:- Is anti-reflux therapy an effective treatment for idiopathic pulmonary...
study (a sub-study). Some people need ERT after Intrabeam (see page 3). Fibrosis (thickening and stiffening of the breast tissue) is the...